Insys Therapeutics Inc. (fka INSYQ)

[tshaq1]

The addition of the new CEO should help reassure the market that INSY is taking the delayed/adjusted earnings seriously. Not only that, but Motahari seems to have a great background (Purdue: big name drugs including Dilaudid and Oxycontin) that could be especially helpful in INSY's current state. I can imagine he had quite the learning experience with Purde, but also a tumultuous experience working with the DEA/FDA on Purdue's products. What we needed was a man of business that can bring a product to market and also sell that product. That's what we got. Syndros will likely be the easiest product he's had to work with over the last couple years. Referencing The Motley Fool's recent article "Why Wasn't Insys Therapeutics' Bounce Bigger?" (link below), the author lists the two following hurdles as the likely culprits: "That internal review focused on the company's processes for estimating and increasing sales allowances and on extended payment terms granted to some customers in the third quarter of 2016." and "Another potential reason why Insys' share price increase was relatively small could be that many remain skeptical about the potential for Syndros. Insys thinks the drug could generate sales of more than $200 million. If that estimate becomes reality, the stock should be valued much more highly than it is right now." The new CEO is the answer to both of these. ALL IMO.

[url][/url][tag]https://www.fool.com/investing/2017/03/24/why-wasnt-insys-therapeutics-bounce-bigger.aspx[/tag]

TShaq